Keppra XR® offers convenient dosing to help patients stay compliant1,2

  • Simple once-daily dosing available in 500-mg and 750-mg dosage strengths
  • Flexible dosing—can be taken either during the day or night, with or without food
    — Should be taken at the same time every day or night
  • No titration required

Simple dosing

Pills Dosing Chart
  • Effective starting dose: 1000 mg/day (2 × 500-mg tablets once daily)
  • Dosage adjustment: If needed, daily dosage may be adjusted in increments of 1000 mg every 2 weeks to a maximum recommended daily dose of 3000 mg.
  • Missed doses: If a dose is missed, the next dose should not be doubled. If only a few hours have passed since a missed dose, instruct patients to take Keppra XR® as soon as remembered and return to their regular schedule. If it is almost time for the next dose, instruct patients to resume their regular schedule.
  • Dosing for impaired renal function: Dosing must be individualized according to the patient’s renal function status. See table below.

Keppra XR® should be gradually withdrawn to minimize the potential for increased seizure frequency.

Convenient dosing encourages compliance1,2

  • Patients taking fewer daily doses are less likely to miss doses and to have breakthrough seizures as a result2
  • Once-daily dosing has been shown to provide the greatest likelihood of compliance1
    — 94% of neurologists agree that an AED should be dosed once daily to promote    compliance and help prevent breakthrough seizures3

Dosing for adult patients with impaired renal function

Simple Dosing Chart

In patients with end-stage renal disease on dialysis, it is recommended that immediate-release Keppra® (levetiracetam) be used instead of Keppra XR®. Please see Keppra® Tablets/Oral Solution Prescribing Information or Keppra® Injection Prescribing Information.

IMPORTANT SAFETY INFORMATION

Keppra XR® extended-release tablets are indicated as adjunctive therapy in the treatment of partial onset seizures in patients 16 years of age and older with epilepsy.

Antiepileptic drugs (AEDs) increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Keppra XR® causes somnolence, dizziness, and behavioral abnormalities. The most common adverse reactions observed with Keppra XR® in combination with other AEDs were somnolence and irritability.

The adverse reactions that may be seen in patients receiving Keppra XR® are expected to be similar to those seen in patients receiving immediate-release Keppra® (levetiracetam) tablets.

Keppra® immediate-release tablets cause somnolence and fatigue, coordination difficulties, and behavioral abnormalities (e.g., psychotic symptoms, suicidal ideation, and other abnormalities), as well as hematological abnormalities. In adults experiencing partial onset seizures, the most common adverse reactions observed with Keppra® in combination with other AEDs were somnolence, asthenia, infection, and dizziness.

Keppra XR® should be gradually withdrawn to minimize the potential of increased seizure frequency.

Dosing must be individualized according to the patient’s renal function status. In patients with end stage renal disease on dialysis, it is recommended that immediate-release Keppra® be used instead of Keppra XR®. Please see Keppra.com for the Keppra® immediate-release tablets full prescribing information.

Please see Keppra XR® Medication Guide and Full Prescribing Information.


REFERENCES

1. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouelette VL. How often is medication taken as prescribed?
    A novel assessment technique. JAMA. 1989;261:3273-3277.
2. Cramer JA, Glassman M, Rienzi V. The relationship between poor medication compliance and seizures.
    Epilepsy Behav. 2002;3:338-342.
3. Survey data on file. UCB, Inc.

*With this coupon, your patients pay the first $25 of their Keppra XR® or Keppra® co-pay and we pay the remaining out-of-pocket expense up to a maximum of $30. This coupon may not be repsiption. No cash value. Not valid for prescriptions that are reimbursed, in whole or part, under Medicare (including Medicare Part D), Medicaid, similar federal or state funded programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico), private insurance in the Commonwealth of Massachusetts, or where otherwise prohibited by law. Product dispensed pursuant to program rules and federal and state laws. Claims should not be submitted to any public payor (i.e., Medicare, Medicaid, Medigap, Tricare, VA and DoD) for reimbursement. Offer expires 12/31/2012. UCB may cancel or alter this program at any time without notice.